Buraggi G, Britton K E, Büll U, Emrich D, Fueger G, Winkler C G, Bishop-Delaloye A, Chatal J F, Dienstbier Z, Ell P J
Istituto Nazionale Tumori, Milano, Italy.
Int J Biol Markers. 1986 Sep-Dec;1(3):147-53. doi: 10.1177/172460088600100306.
In September 1985 a task group on the clinical utility of labelled antibodies was founded by the Society of Nuclear Medicine - Europe. This document was elaborated to report the aims and the programs of the group. In September 1986 the European Nuclear Medicine Society decided to participate in this initiative and a joint task group was created. INITIAL DOCUMENT: A. The aims to the Task Group are to monitor, co-ordinate and promote research and clinical application of techniques using radiolabelled antibodies in nuclear medicine. A.1. The Group should develop into a major point of reference, giving scientific and technical support to each member of the Society involved in this field. B. To pursue these purposes it will be necessary to develop the following: B.1. Criteria to evaluate the suitability of antigen-antibody systems for tumour detection and/or therapy. B.2. Criteria for quality control of radioimmunoreagents. B.3. Criteria for the prevention of adverse reactions or damage due to the reagent. B.4. Selection of suitable dosimetric methods for diagnostic or therapeutic applications. B.5. Elaboration of protocols for clinical experiments, including appropriate techniques to be applied in single cases. B.6. Organization of cooperative studies. C. The Task Group should promote: C.1. Informal meetings between the members of the Group. C.2. Workshops open to the members of the Society and other researchers. C.3. Publication of reports in appropriate journals.
1985年9月，欧洲核医学协会成立了一个关于标记抗体临床应用的特别工作组。编写本文件是为了报告该小组的目标和计划。1986年9月，欧洲核医学协会决定参与这一倡议，并成立了一个联合特别工作组。初始文件：A. 特别工作组的目标是监测、协调和促进核医学中使用放射性标记抗体技术的研究和临床应用。A.1. 该小组应发展成为一个主要的参考点，为协会中参与该领域的每个成员提供科学和技术支持。B. 为实现这些目标，有必要开展以下工作：B.1. 评估抗原-抗体系统用于肿瘤检测和/或治疗适用性的标准。B.2. 放射免疫试剂质量控制标准。B.3. 预防试剂引起的不良反应或损害的标准。B.4. 选择适用于诊断或治疗应用的剂量测定方法。B.5. 制定临床实验方案，包括适用于单个病例的适当技术。B.6. 组织合作研究。C. 特别工作组应促进：C.1. 小组成员之间的非正式会议。C.2. 面向协会成员和其他研究人员的研讨会。C.3. 在适当的期刊上发表报告。
